Scynexis Inc(SCYX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.84 | Insider Own | 3.96% | Shs Outstand | 9.9M | Perf Week | - |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 20.45% | Insider Trans | - | Shs Float | 9.6M | Perf Month | -17.75% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.72 | Inst Own | 56.32% | Short Float | 4.4% | Perf Quarter | 0.8% |
| Income | -0.01B | P/S | 1.97 | EPS this Y | -113.97% | Inst Trans | 13.05% | Short Ratio | 1.51 | Perf Half Y | -51.82% |
| Sales | 0.02B | P/B | 0.56 | EPS next 5Y | -15.4% | ROA | -15.09% | Short Interest | 0.42M | Perf YTD | -24.89% |
| Book/sh | 6.73 | P/C | 0.7 | EPS past 3/5Y | 51.09% 49.3% | ROE | -18.38% | 52W High | -58.33% ($9.12) | Perf Year | -36.92% |
| Cash/sh | 5.44 | P/FCF | - | Sales past 3/5Y | 59.35% - | ROIC | -14.97% | 52W Low | 7.65% ($3.53) | Perf 3Y | -72.06% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.39% | Gross Margin | - | Volatility(W/M) | 4.67% 7.32% | Perf 5Y | -90.65% |
| Dividend TTM | - | EV/Sales | -0.75 | Sales Y/Y TTM | 489.78% | Oper. Margin | -117.61% | ATR (14) | 0.28 | Perf 10Y | -98.64% |
| Dividend Ex-Date | - | Quick Ratio | 9.56 | EPS Q/Q | 156.51% | Profit Margin | -53.27% | RSI (14) | 36.67 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.56 | Sales Q/Q | -82.77% | SMA20 | -9.94% ($4.22) | Beta | 1.12 | Target Price | $36.33 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/10 | SMA50 | -18.08% ($4.64) | Rel Volume | 0.16 | Prev Close | $3.81 |
| Employees | 18 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 224.33% 192.65% | SMA200 | -31.7% ($5.56) | Avg Volume(3M) | 0.28M | Price | $3.8 |
| IPO | 2014/5/2 | Option/Short | Yes/Yes | Trades | 254 | Volume | 43,176 | Change | -0.26% |
🧬 This is a US biotech developing innovative antifungal agents to treat drug-resistant fungal infections. Its FDA-approved antifungal BREXAFEMME® (ibrexafungerp) is used to treat vulvovaginal candidiasis, and the company has licensed it out to GSK to drive global development and commercialization. It is also developing a next-generation antifungal pipeline candidate, SCY-247.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 16% of its average volume.
SCYX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -114.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $197. Peers typically go for $197. Compared with its own 1-year average, it is 30% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -90.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 56.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #63 of 83 in the industry
Based on market cap of $38M.
FAQ
What kind of company is SCYX?
SCYX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SCYX?
The market cap of SCYX is approximately $38M, ranking 4,989 within its sector.
What is the 52-week high and low for SCYX?
SCYX has recorded a 52-week high of $9.12 and a low of $3.53.
